Silas Inman

At ASH 2024, Annette von Drygalski, MD, PharmD, described the paradigm shift that has taken place in hemophilia over the past decade.

Retina specialists and an AI screening tool trained to measure geographic atrophy agreed in a majority of cases, potentially expediting clinical trial enrollment and increasing consistency in measuring the disease.

The anti-VEGF agent tarcocimab significantly improved diabetic retinopathy severity score compared with SHAM in a phase 3 study.

Large language model AI tools like ChatGPT quickly, easily, and effectively modified dense medical information into grade 6 to 8 reading levels.

A multi-target stool RNA test effectively screened individuals age 45 and older for colorectal cancer and advanced adenomas.

Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.

Etrasimod demonstrated rapid and significant symptomatic improvement, with differences compared to placebo evident as early as 2 days after initiation of treatment in patients with ulcerative colitis.

Completion of prescription app-based cognitive behavioral therapy using Mahana IBS significantly reduced symptom severity and perceived stress for patients with irritable bowel syndrome.

Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.

Consumption of fruit and vegetables was found to be protective while consuming sweet snacks and candy along with supercenters and warehouse clubs as a primary food source were determined to be risk factors for early onset colorectal cancer mortality.

The 15 mg dose of tirzepatide was the most efficacious GLP-1 agonist for obesity management in patients without diabetes in a systemic review of data from MEDLINE and Embase databases.

Post-hoc analysis clarifies efficacy of upadacitinib for patients with moderately to severely active Crohn's disease with a CDAI of 220 or more.

Antibiotics followed by oral SER-109 demonstrated a low rate of recurrent clostridioides difficile infection through week 8, regardless of the number of prior episodes.

Extended induction treatment with upadacitinib 45 mg led to achievement of clinical response in a clinically meaningful proportion of patients with ulcerative colitis who do not respond to 8 weeks of induction therapy.

RBX2660 reduced clostridioides difficile infection recurrence at 8 weeks, with a sustained clinical response through 6 months, in an open-label phase 3 cohort of patients representative of real-world clinical practice.

Treatment with guselkumab resulted in greater improvements across key clinical and endoscopic/histologic outcome measures at week 12 compared with placebo in patients with moderately to severely active ulcerative colitis with or without a history of inadequate response or intolerance to advanced therapy.

Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.

Twelve additional weeks of subcutaneous risankizumab induction was efficacious and well-tolerated in patients with Crohn's disease following an initial risankizumab 12-week induction dose.

Risankizumab induction relieved Crohn's disease symptoms and maintenance doses were effective in resolving abdominal pain, with other mixed findings for other patient-reported outcomes in the maintenance phase.

Treatment with terlipressin led to better long-term clinical outcomes for patients with hepatorenal syndrome who received a liver transplant.

On-demand vonoprazan at all investigated doses was significantly better than placebo in providing rapid and sustained relief from heartburn episodes in patients with nonerosive reflux disease.

Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.

A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.

FDA grants emergency use authorization to a rapid point-of-care test to detect COVID-19 infection.

Results of a recent study from ASH 2019 is suggesting a combination of navitoclax and ruxolitinib could improve outcomes for patients with myelofibrosis.

Results of the phase 2 MANIFEST study presented at ASH 2019 suggest CPI-0610 could be an effective treatment for patients with refractory or intolerant advanced myelofibrosis.

The rAAV2/2-ND4 gene therapy GS010 elicited continuous bilateral improvements in BCVA from week 48 to week 96 for patients with Leber hereditary optic neuropathy.

Intraocular pressure at day 7 post MicroShunt implantation may be useful for predicting outcomes 1-year post procedure for patients with glaucoma.

A 0.002% concentration of sepetaprost demonstrated promising reductions in intraocular pressure (for patients with primary open-angle glaucoma or ocular hypertension.

Intravitreal aflibercept injection showed a high level of ≥2-step improvement in DRSS compared with sham for patients with moderately severe to severe nonproliferative diabetic retinopathy.